Thus, CLW improved the diabetic symptoms by suppressing hepatic insulin resistance by potentiating hepatic insulin signaling as much as rosiglitazone in non-obese type 2 diabetic rats with impaired insulin secretion. This evidence concerns the gene INS and Insulin resistance.